Loading

Journal of Immunology and Clinical Research

Divide and Conquer: Using Patient Stratification to Optimize Therapeutic Drug Development in Inflammatory Bowel Disease

Review Article | Open Access

  • 1. F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Department of Gastroentrology, Cedars-Sinai Medical Hospital, USA
+ Show More - Show Less
Corresponding Authors
Janine Bilsborough, F.Widjaja Inflammatory Bowel and Immunobiology Research Institute, CedarsSinai Medical Center, Los Angeles, CA, USA
Abstract

Inflammatory Bowel Disease (IBD) is a complex and heterogeneous disorder. Clinical symptoms can vary widely among patients and etiology of the disease is likely influenced by numerous factors including genetic predisposition and environmental factors, as well as social behaviors such as smoking and diet. It is likely that IBD comprises several disorders that share clinical features with the two most well accepted classifications of IBD, Crohn’s Disease (CD) and Ulcerative Colitis (UC), being two extremes of a continuum. Such complexity has hampered the effectiveness of current treatment and has slowed the development of successful therapeutics. In this review, we discuss a personalized medicine approach that may promote both faster and more efficient development of new therapies and potentially increase the efficacy of existing drugs.

Keywords


•    Crohn’s disease
•    Ulcerative colitis
•    Personalized medicine
•    Patient stratification
 

Citation

Bilsborough J, McGovern DPB, Targan SR (2014) Divide and Conquer: Using Patient Stratification to Optimize Therapeutic Drug Development in Inflammatory Bowel Disease. J Immunol Clin Res 2(1): 1017.

ABBREVIATIONS

IBD: Inflammatory Bowel Disease; CD: Crohn’s Disease; UC: Ulcerative Colitis; MRUC: Medically Refractory Ulcerative Colitis; EIM: Extra-Intestinal Manifestations; FDA: Food and Drug Administration; GWAS: Genome-Wide Association Studies; pANCA: perinuclear-staining Anti-Neutrophil Cytoplasmc Antibodies; ASCA: Anti-Saccharmyces Cerevisiae Antibodies; OmpC: Outer membrane Porin C.

INTRODUCTION

In the world of computer science, divide-and-conquer algorithms break down a complex problem into multiple ‘subproblems’ of the same or similar type until these problems become simple enough to be solved directly. Thus the technique of simplification is a powerful tool for solving complexity.

The complexity and heterogeneity of Inflammatory Bowel Disease (IBD) is widely accepted. Etiology of the disease is likely influenced by numerous factors including genetic predisposition and environmental factors such as the microbiota, as well as social behaviors such as smoking and diet. Moreover, the presentation of IBD varies in terms of clinical symptoms including location of disease involvement, disease severity, associated complications, presence of extra-intestinal manifestations (EIMs), and age at diagnosis. Thus it is likely that IBD comprises several disorders that share clinical features and, currently, the two most well accepted classifications of IBD, Crohn’s Disease (CD) and Ulcerative Colitis (UC), are two extremes of a continuum.

Such complexity has contributed to the frustration of successful drug development and new innovative therapies in recent years. The last novel class of biologics (non-anti-TNF derivatives) approved for IBD was in 2008 with the approval of Natalizumab [1]. The failure of new therapies to come to market is not due to lack of effort. Many novel classes of therapeutics have been in clinical trials for IBD in recent years [2] but none, other than Natalizumab, have made it to approval as of December, 2013. However, the FDA advisory committee has recently recommended approval for Vedolizumab, a monoclonal antibody specific for the α4β7 integrin, for the treatment of moderate to severe UC and CD.

Although current therapeutic trials are hampered by the need for large subject numbers to overcome high placebo rates and the limitations of traditional endpoint measurements to detect low response rates [3], the slow rate of drug development in IBD may be due to a more fundamental issue related to disease complexity. Arguably, the most surprising drug failure for IBD in recent years has been the anti-IL-17A monoclonal antibody, Secukinumab. Trial data showed no therapeutic effect in CD patients and indeed, some patients demonstrated acute exacerbation of disease following treatment [4]. These data were unexpected since anti-IL17A treatment is efficacious for Psoriasis [5] and more recently, Ankylosing Spondylitis [6], both of which are inflammatory diseases that demonstrate significant overlap with IBD in terms of biological pathways and genetic susceptibility associations [7]. Such results highlight the fact that investigators still lack a fundamental understanding of how the multifactorial components that contribute to the development of IBD pathobiology can influence our ability to modify the disease course.

It is clear then, that a path to simplification of this complex disease is a necessary step toward the advancement of successful therapeutics. In order to reduce the complexity of this disease it may be necessary to embrace the approach of patient stratification to enrich for patient sub-groups that have similar phenotypes irrespective of whether these are defined using clinical, serological, genetic, histopathological, biological, microbiomal or by other parameters.

Clinical phenotype classifications, such as the Montreal classification [8], have helped to stratify patient groups with similar manifestation of disease. However, given the broad etiology of the disease, additional stratification through serology, genetics and biological processes is expected to further contribute to the identification of increasingly homogenous patient groups. There is evidence, for example, that serological markers not only differentiate CD from UC, but also define subgroups within either disease group. Anti-neutrophil cytoplasmic antibodies (ANCA), for example, define subgroups of patients with colonic disease both in UC and CD. Moreover, in the absence of perinuclearstaining ANCA (pANCA), the expression of both IgG and IgA of a second autoantibody, anti-saccharmyces cerevisiae (ASCA), has been associated with fibrostenotic and perforating disease [9]. A panel of these antibodies that recognize bacterial proteins have been developed to help phenotypically classify IBD (reviewed in [10] and summarized in Table 1). Importantly, the association of serologies with different IBD phenotypes implies that patients with a particular disease phenotype respond to bacterial antigens differently. This suggests that different biological pathways may be more prominent in certain disease phenotypes than others and that many factors may influence these biological pathways including the local microbiota and/or host genetic background. Indeed, one study investigating genetic polymorphisms within a gene encoding a C-type lectin critical for protection against fungal infection in mice, found a single nucleotide polymorphism within that gene associated with medically refractory UC (MRUC) in humans [11]. Furthermore, the observation that murine norovirus is crucial for the development of CD-like features in the ATG16L1 hypomorphic mouse potentially implicates a viral trigger in IBD pathogenesis [12]. These findings support the concept that genetic factors influence the host response to microbiota and potentially drive distinct clinical phenotypes.

Genetic studies in IBD have also confirmed the complexity of IBD, with a recent study extending the number of IBD through in vitro and ex vivo cellular assays from patient samples as well as microbiomal, metaproteomic and metabolomics data from gut specimens [20]. One goal that precipitated the development of this resource is to facilitate the discovery of novel therapeutics that are designed to be most effective in a preselected patient populations. Consequently, clinical trial design for therapeutics arising from these investigational studies will, by definition, be better informed through the use of biomarkers and genotypic information. Given these pre-screened populations would be selected based on their likelihood of response to the therapy, clinical trial sizes would be expected to be greatly reduced, saving both time and resources.

The focus of our work is to improve on the success and speed with which innovative therapies move through the drug development process. Through the generation of this biorepository and patient database 26 years ago we instigated a “bedside-to-bench” approach for therapeutic target discovery. Now, we are focused on the completion of the equation with the reverse “bench-to-bedside” focus on personalized medicine that selects a patient population predicted to respond to a particular therapeutic. We envision that this holistic approach to target identification and drug development will be the key to achieving the much needed, novel therapies for treatment of IBD and possibly other similar immune-related conditions.

Table 1: Antibody Panel for IBD Classification.

Antibody Target Predominant 
Disease Location
Disease Behavior
pANCA Nuclear envelop 
protein of 
neutrophils
Colon Distal colitis
ASCA Saccharomyces 
cerevisiae cell wall
Small Bowel Fibrostenosing, Internal Penetration
OmpC Omp-C transport 
protein of 
Escherichia coli
Small Bowel Fibrostenosing, Internal Penetration
12 Pseudomonasassociated sequence 
I2
Small Bowel Fibrostenosing, Internal Penetration
Cbir1 Bacterial flagellin 
CBir1
Small Bowel Fibrostenosing, 
Internal Penetration

 

CONFLICT OF INTEREST

DPM is on the advisory boards of UCB and Lily. SRT is on the advisory boards of Takeda Pharmaceuticals International and Prometheus Laboratories Inc.

REFERENCES

1. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005; 353: 1912-1925.

2. Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut. 2012; 61: 918-932.

3. Lahiff C, Kane S, Moss AC. Drug development in inflammatory bowel disease: the role of the FDA. Inflamm Bowel Dis. 2011; 17: 2585-2593.

4. Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012; 61: 1693-1700.

5. Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, et al. Secukinumab induction and maintenance therapy in moderateto-severe plaque psoriasis: a randomized, double-blind, placebocontrolled, phase II regimen-finding study. Br J Dermatol. 2013; 168: 402-411.

6. Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013; 382: 1705-1713.

7. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012; 491: 119-124.

8. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006; 55: 749-753.

9. Vasiliauskas EA, Plevy SE, Landers CJ, Binder SW, Ferguson DM, Yang H, et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn’s disease define a clinical subgroup. Gastroenterology. 1996; 110: 1810-1819.

10. Sellin JH, Shah RR. The promise and pitfalls of serologic testing in inflammatory bowel disease. Gastroenterol Clin North Am. 2012; 41: 463-482.

11. Iliev ID, Funari VA, Taylor KD, Nguyen Q, Reyes CN, Strom SP, et al. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science. 2012; 336: 1314-1317.

12. Cadwell K, Patel KK, Maloney NS, Liu TC, Ng AC, Storer CE, et al. Virusplus-susceptibility gene interaction determines Crohn’s disease gene Atg16L1 phenotypes in intestine. Cell. 2010; 141: 1135-1145.

13. Hirano A, Yamazaki K, Umeno J, Ashikawa K, Aoki M, Matsumoto T, et al. Association study of 71 European Crohn’s disease susceptibility loci in a Japanese population. Inflamm Bowel Dis. 2013; 19: 526-533.

14. Adler J, Rangwalla SC, Dwamena BA, Higgins PD. The prognostic power of the NOD2 genotype for complicated Crohn’s disease: a metaanalysis. Am J Gastroenterol. 2011; 106: 699-712.

15. Arijs I, Li K, Toedter G, Quintens R, Van Lommel L, Van Steen K, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut. 2009; 58: 1612-1619.

16. Hlavaty T, Ferrante M, Henckaerts L, Pierik M, Rutgeerts P, Vermeire S. Predictive model for the outcome of infliximab therapy in Crohn’s disease based on apoptotic pharmacogenetic index and clinical predictors. Inflamm Bowel Dis. 2007; 13: 372-379.

17. Dubinsky MC, Mei L, Friedman M, Dhere T, Haritunians T, Hakonarson H, et al. Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2010; 16: 1357-1366.

18. Dubinsky MC, Kugathasan S, Kwon S, Haritunians T, Wrobel I, Wahbeh G, et al. Multidimensional prognostic risk assessment identifies association between IL12B variation and surgery in Crohn’s disease. Inflamm Bowel Dis. 2013; 19: 1662-1670.

19. Haritunians T, Taylor KD, Targan SR, Dubinsky M, Ippoliti A, Kwon S, et al. Genetic predictors of medically refractory ulcerative colitis. Inflamm Bowel Dis. 2010; 16: 1830-1840.

20. Tong M, Li X, Wegener Parfrey L, Roth B, Ippoliti A, Wei B, et al. A modular organization of the human intestinal mucosal microbiota and its association with inflammatory bowel disease. PLoS One. 2013; 8: e80702

Received : 19 Jan 2014
Accepted : 21 Jan 2014
Published : 27 Jan 2014
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X